Haiping Liang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Haiping Liang has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Anan Wang
First School of Clinical Medicine of Lanzhou University, Lanzhou, China
1 shared publication - Bei Liu
Department of Hematology, The First Hospital of Lanzhou University, Lanzhou, China
1 shared publication - Chongchong Ren
Shaanxi Provincial People’s Hospital, Xi’an, China
1 shared publication - Jiajing Li
First School of Clinical Medicine of Lanzhou University, Lanzhou, China
1 shared publication - Jiangang Guo
First School of Clinical Medicine of Lanzhou University, Lanzhou, China
1 shared publication - Xiaoda Yu
First School of Clinical Medicine of Lanzhou University, Lanzhou, China
1 shared publication
Latest Publications
- Open Access
- 31 August 2026
- Published by Springer Nature in Annals of Hematology
Retrospective evaluation of venetoclax-based regimen in newly diagnosed and relapsed/refractory acute myeloid leukemia: Efficacy determinants, survival outcomes, and model validation
Treatment response, survival outcomes, and factors related to venetoclax (VEN)-based therapy were assessed in patients with acute myeloid leukemia (AML), including newly diagnosed AML (ND-AML) and relapsed/refractory AML (R/R AML). We also developed a model to predict composite complete remission (CRc) after the first treatment cycle. This retrospective study included 216 patients with AML who received VEN-based regimens at the First Hospital of Lanzhou University between March 2020 and May 2025. Treatment response, overall survival (OS), and factors related to CRc and OS were evaluated. A multivariable model for CRc was developed and internally validated using 1,000 bootstrap resamples. Of the 216 patients, 165 had ND-AML and 51 had R/R AML. CRc was achieved in 74.5% and 39.2% of patients, respectively. In ND-AML, failure to achieve CRc, older age, and NF1 mutation were independently associated with shorter OS. In R/R AML, a lower pretreatment white blood cell count and a higher bone marrow blast percentage were associated with CRc, whereas failure to achieve CRc was associated with higher mortality. The final six-predictor model included AML status, age, bone marrow blast percentage, platelet count, Eastern Cooperative Oncology Group (ECOG) performance status, and TET2 mutation. Its apparent area under the receiver operating characteristic curve (AUC) was 0.841 (95% confidence interval, 0.785–0.897). The fixed CRc score yielded time-dependent OS AUCs of 0.788 at 6 months and 0.695 at 12 months. The model may be useful for estimating early treatment response, although external validation is needed before routine clinical application.
- 31 August 2026
- Published by Springer Nature in Annals of Hematology
Open AccessRetrospective evaluation of venetoclax-based regimen in newly diagnosed and relapsed/refractory acute myeloid leukemia: Efficacy determinants, survival outcomes, and model validation
Treatment response, survival outcomes, and factors related to venetoclax (VEN)-based therapy were assessed in patients with acute myeloid leukemia (AML), including newly diagnosed AML (ND-AML) and relapsed/refractory AML (R/R AML). We also developed a model to predict composite complete remission (CRc) after the first treatment cycle. This retrospective study included 216 patients with AML who received VEN-based regimens at the First Hospital of Lanzhou University between March 2020 and May 2025. Treatment response, overall survival (OS), and factors related to CRc and OS were evaluated. A multivariable model for CRc was developed and internally validated using 1,000 bootstrap resamples. Of the 216 patients, 165 had ND-AML and 51 had R/R AML. CRc was achieved in 74.5% and 39.2% of patients, respectively. In ND-AML, failure to achieve CRc, older age, and NF1 mutation were independently associated with shorter OS. In R/R AML, a lower pretreatment white blood cell count and a higher bone marrow blast percentage were associated with CRc, whereas failure to achieve CRc was associated with higher mortality. The final six-predictor model included AML status, age, bone marrow blast percentage, platelet count, Eastern Cooperative Oncology Group (ECOG) performance status, and TET2 mutation. Its apparent area under the receiver operating characteristic curve (AUC) was 0.841 (95% confidence interval, 0.785–0.897). The fixed CRc score yielded time-dependent OS AUCs of 0.788 at 6 months and 0.695 at 12 months. The model may be useful for estimating early treatment response, although external validation is needed before routine clinical application.